News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Colorectal Cancer
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Library
Feb 21, 2025, 16:41
New Paper Alert: Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach
Blog
Feb 21, 2025, 15:06
The full press release of ELLOK is out
Blog
Feb 21, 2025, 14:59
Siobhan Freeney: What women in Ireland need to know about Dense Breasts and Cancer
Blog
Feb 21, 2025, 14:54
CEO of the Canadian Cancer Society about the inequities in cancer care across populations in Canada - UICC
Career
Feb 21, 2025, 14:34
Kristiyana Kaneva is appointed as Medical Director of Oncology Early Development at AbbVie
Blog
Feb 21, 2025, 14:27
Douglas Flora: A Cure for Cancer - Closer Than We Think?
Blog
Feb 21, 2025, 14:26
14th Biennial Childhood Leukemia and Lymphoma Symposium: Advancing Research and Collaboration in Budapest
Blog
Feb 21, 2025, 14:13
Rachel Chown: An incredibly inspiring and humbling talk from Liubov Lisovska
Science
Feb 21, 2025, 14:08
Survival improvement of patients with melanoma brain or leptomeningeal metastases in Denmark - CCIT-DK
Science
Feb 21, 2025, 13:51
Aaron Sverdlov: Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities
Blog
Feb 21, 2025, 13:40
Breaking barriers: ensuring equal cancer care access for diverse communities - SPCC
Blog
Feb 21, 2025, 13:29
Sana Al Sukhun: Enjoyed joining Emirates Oncology Society's SABCS